The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer .According to the result of TAX317,the ORR of second line standard chemotherapy was 5- 8%. We expect the ORR was 20%. Using PASS11, we calculated the sample size of this study was 39 , according to 10% censoring,the expected sample size is 43.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18,Pathologically proven Non squamous non small cell lung cancer
* No-drive gene mutaion (EGFR、ALK、ROS1) by NGS
* Progress after second line
* PS score 0-2
You may not be if
Patients received second line treatment
Patients received treatment of Anlotinib or Docetaxel